IL17A (Interleukin 17A)

At the same time, A. muciniphila administration improves cognitive deficits, alleviates neuroinflammation and Aβ deposition via AhR/NF-κB/NLRP3 signaling pathway in APP/PS1 mice. In summary, our findings suggest A. muciniphila is a promising approach for preventing AD progression by microbiota-gut-brain axis.

Transcriptomic analysis revealed that 3D-hUC-MSCs modulated signaling pathways associated with inflammation and innate immune responses. Our findings suggest that the 3D microcarrier-bioreactor system holds promise as a strategy to enhance the therapeutic potential of hUC-MSCs, particularly in the treatment of immune-mediated disorders such as psoriasis.

Acidic small-molecule inhibitors, PEGylated derivatives, and antibody-functionalized lipid nanoparticles collectively address potency, exposure, and immune context. Together, these approaches outline an integrated framework for treating inflammatory diseases and immunosuppressive tumor microenvironments.

This review supports early screening, metabolic monitoring, and lifestyle changes as critical components of long-term psoriatic therapy. Recognising psoriasis as a systemic condition is critical for improving overall patient outcomes, lowering morbidity, and avoiding long-term consequences.

Our findings indicate that Grg3 confers protective effects in a murine model of imiquimod-induced psoriasis-like dermatitis. The potential therapeutic properties of Grg3 potentially involve modulation of NLRP3 inflammasome activation, suppression of NF-κB signaling, and restoration of Th17/Treg cell homeostasis.

Additionally, organ-on-a-chip technology confirmed that SFALCA showed no significant toxicity to the liver. In conclusion, this study elucidates the active components and mechanisms of SFALCA in treating IBD and assesses its safety, providing a reliable in vitro platform for future therapeutic strategies.

IL-6 may serve as a biomarker reflecting both inflammation and tissue damage in PSS. Note: CECD, corneal endothelial cell density; RECL, relative decrease in CECD loss between the affected eye and the fellow eye.

Undernutrition exacerbates disease severity through local and systemic immune dysregulation and microbial shifts. Our results support new treatments targeting diet and microbiota to control VL.

In pregnant mice, maternal DHA supplementation mitigated LPS-induced FGR by suppressing NF-κB-mediated inflammatory signaling, modulating gut microbiota composition, and supporting intestinal barrier function, highlighting a potential nutritional strategy to alleviate inflammation-associated adverse pregnancy outcomes.

Preclinical studies have demonstrated that genetic or pharmacologic inhibition of IL-32 attenuates experimental arthritis severity, underscoring its therapeutic potential. Herein, we provide a comprehensive, up-to-date review of the current understanding of IL-32 biology in RA and its translational implications.

Network pharmacology identified 239 potential targets, with core targets including TP53, TNF, STAT3, and EGFR, significantly enriched in p53, PI3K-Akt, TNF, and IL-17 pathways. Disease association networks indicate luteolin's potential to intervene in neurological, circulatory, metabolic, immune, digestive, respiratory disorders, and multiple tumors, exhibiting typical multi-target comprehensive regulatory characteristics.

Structural modeling uncovered a three-way junction and 3' triple helix in lncRNA. Collectively, these data suggest that circulating inflammatory rewiring is associated with checkpoint-rich suppressor expansion and tumor immune quiescence, outlining integrated myeloid- and RNA-directed strategies for cancer research.